In this study, using the currently available clinical grade genotyping panels in WD/DD liposarcoma, 20/20 (100%) patient samples tested had CDK4 amplified and 16/16 (100%) patient samples tested had MDM2 amplified. This evidence concerns the gene MDM2 and Wilson disease.